Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Apr 8, 2021
    - New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve
    - Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy
    - TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
  • Apr 6, 2021
    - New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding
    - XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented patients with one-month or three-month use of DAPT
    - Recent data demonstrate XIENCE with short DAPT does not increase cardiac events and reduces severe bleeding, further confirming the leading safety profile of the XIENCE stent
  • Mar 31, 2021
    - FDA Emergency Use Authorization permits asymptomatic, non-prescription, over-the-counter self use for people with or without symptoms
    - The BinaxNOW COVID-19 Self Test is identical to the professional-use test, used since August 2020, bringing the most studied and widely used rapid antigen test to retail shelves across the country
    - BinaxNOW Self Test will be available nationwide and in large quantities at major food, drug and mass merchandiser retailers nationally and will be priced affordably, similar to common over-the-counter (OTC) tests
    - Together with vaccines, serial testing of asymptomatic people will help restore a sense of safety in everyday settings where people gather
    - Asymptomatic multi-test authorization also applies to BinaxNOW professional-use test
  • Mar 8, 2021
    - Newly FDA-approved system allows a patient to both communicate with a physician and remotely receive stimulation settings in real time regardless of location*
    - NeuroSphere Virtual Clinic utilizes advancements made in digital technology to optimize care through intuitive tools that enhance therapy management
    - Virtual clinic technology can change the treatment approach for patients who live far from necessary medical care or who are burdened by visiting the doctor in person
  • Mar 5, 2021
    -- Abbott's Alinity™ m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms
    -- The test helps save on much-needed testing supplies since it allows for testing for all four viruses with one swab
    -- Assay will run on Abbott's most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes
    -- Abbott also received updated EUA for asymptomatic usage of its Alinity m SARS-CoV-2 assay
  • Jan 26, 2021
    - Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic
    - Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers
    - Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision
    - Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
    - Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads
    - Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends
    - Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
  • Jan 20, 2021
    - New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population
  • Jan 14, 2021
    - New app will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data
    - NeuroSphere myPath will be available in the Apple App Store in the coming weeks and will be compatible with the latest iOS operating system
  • Jan 12, 2021
    - Abbott will complete the U.S. government order for 150 million BinaxNOW COVID-19 tests this week and will supply 30 million additional tests through March via a new government order
    - Company is in final stages of completing its self-funded capacity expansion across U.S. manufacturing sites
    - Abbott has the most advanced and comprehensive COVID-19 rapid test portfolio available today, including ID NOW, BinaxNOW, the BinaxNOW at-home test and the NAVICA app
    - Workplaces, universities, schools and other qualified organizations that need frequent and affordable testing can now directly procure BinaxNOW tests from Abbott
  • Jan 11, 2021
    - The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott's i-STAT™ Alinity™ handheld device
    - Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%
    - The test simultaneously measures biomarkers UCH-L1 and GFAP, proteins found in the blood after a concussion or head trauma
    - Building on this initial clearance, Abbott is also working on a test that would use whole blood on i-STAT at the point of care, and developing a test for its Alinity™ i and ARCHITECT® core laboratory instruments under FDA breakthrough designation
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?